Coloplast (CLPBY) faces operational challenges, with four consecutive top-line misses and reduced growth expectations, but retains a strong core franchise. CLPBY's CEO search remains unresolved, and ...

Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture ...

Coloplast interim CEO Lars Rasmussen has today informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, ...

Coloplast delivered Q1 organic growth of 6% and EBIT growth 1 in constant currencies of 3%. Reported revenue in DKK grew 0%, reflecting 4%-points negative impact from currencies. Return on invested ...

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment ...

The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Coloplast Group strategy. Over the last couple of months, ...

On Monday, Barclays (LON:BARC) analysts downgraded Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY) stock rating from Overweight to Equalweight and reduced the price target to DKK750.00 from DKK1,010 ...

(Bloomberg) — Coloplast A/S fired its chief executive officer to restore investor confidence after the medical equipment maker failed to deliver sufficient shareholder returns. That’s according to ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...

On Monday, RBC Capital Markets analyst Jack Reynolds-Clark revised the rating for Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY), elevating it from Sector Perform to Outperform. Accompanying this ...

On Wednesday, UBS analyst changed the rating for Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY) from Sell to Neutral, maintaining a price target of DKK858.00. The revision follows a reassessment of ...